About: Liposomal paclitaxel formulations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Liposomal paclitaxel formulations Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Over the past three decades, taxanes represent one of the most important new classes of drugs approved in oncology. Paclitaxel (PTX), the prototype of this class, is an anti-cancer drug approved for the treatment of breast and ovarian cancer. However, notwithstanding a suitable premedication, present-day chemotherapy employing a commercial preparation of PTX (Taxol (R)) is associated with serious side effects and hypersensitivity reactions. Liposomes represent advanced and versatile delivery systems for drugs. Generally, both in vivomice tumor models and human clinical trials demonstrated that liposomal PTX formulations significantly increase a maximum tolerated dose (MTD) of PTX which outperform that for Taxol (R). Liposomal PTX formulations are in various stages of clinical trials. LEP-ETU (NeoPharm) and EndoTAG (R)-1 (Medigene) have reached the phase II of the clinical trials; Lipusu (R) (Luye Pharma Group) has already been commercialized. Present achievements in the preparation of various liposomal formulations of PTX, the development of targeted liposomal PTX systems and the progress in clinical testing of liposomal PTX are discussed in this review summarizing about 30 years of liposomal PTX development. Over the past three decades, taxanes represent one of the most important new classes of drugs approved in oncology. Paclitaxel (PTX), the prototype of this class, is an anti-cancer drug approved for the treatment of breast and ovarian cancer. However, notwithstanding a suitable premedication, present-day chemotherapy employing a commercial preparation of PTX (Taxol (R)) is associated with serious side effects and hypersensitivity reactions. Liposomes represent advanced and versatile delivery systems for drugs. Generally, both in vivomice tumor models and human clinical trials demonstrated that liposomal PTX formulations significantly increase a maximum tolerated dose (MTD) of PTX which outperform that for Taxol (R). Liposomal PTX formulations are in various stages of clinical trials. LEP-ETU (NeoPharm) and EndoTAG (R)-1 (Medigene) have reached the phase II of the clinical trials; Lipusu (R) (Luye Pharma Group) has already been commercialized. Present achievements in the preparation of various liposomal formulations of PTX, the development of targeted liposomal PTX systems and the progress in clinical testing of liposomal PTX are discussed in this review summarizing about 30 years of liposomal PTX development. (en)
Title	Liposomal paclitaxel formulations Liposomal paclitaxel formulations (en)
skos:prefLabel	Liposomal paclitaxel formulations Liposomal paclitaxel formulations (en)
skos:notation	RIV/00027162:_____/12:#0000927!RIV13-MZE-00027162
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(GAP304/10/1951), P(GBP503/12/G147), Z(MZE0002716202)
http://linked.open...iv/cisloPeriodika	3
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Turánek, Jaroslav Koudelka, Štěpán
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Výzkumný ústav veterinárního lékařství, v.v.i.
http://linked.open...dnocenehoVysledku	147176
http://linked.open...ai/riv/idVysledku	RIV/00027162:_____/12:#0000927
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Paclitaxel; Liposome; Drug targeting; Drug delivery systems; Anti-cancer drugs (en)
http://linked.open.../riv/klicoveSlovo	Paclitaxel Anti-cancer drugs Drug delivery systems Drug targeting Liposome
http://linked.open...odStatuVydavatele	NL - Nizozemsko
http://linked.open...ontrolniKodProRIV	[216BF1DA2396]
http://linked.open...i/riv/nazevZdroje	Journal of Controlled Release
http://linked.open...in/vavai/riv/obor	FR
http://linked.open...ichTvurcuVysledku	2 (xsd:int)
http://linked.open...cetTvurcuVysledku	2 (xsd:int)
http://linked.open...vavai/riv/projekt	Centre for studies on toxicity of nanoparticles Nanoliposomes for development of recombinant vaccines and targetted immunotherapeutics
http://linked.open...UplatneniVysledku	2012
http://linked.open...v/svazekPeriodika	163
http://linked.open...iv/tvurceVysledku	Koudelka, Štěpán Turánek, Jaroslav
http://linked.open...ain/vavai/riv/wos	000312266500007
http://linked.open...n/vavai/riv/zamer	Animal disease research, prevention and food chain protection
issn	0168-3659
number of pages	13 (xsd:int)
http://bibframe.org/vocab/doi	10.1016/j.jconrel.2012.09.006

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 49 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software